Merck & Co., Inc. Financial Highlights Package Third Quarter 2023 Table of Contents Table 1: GAAP P&L.....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter..................2 Table 2a: GAAP to Non-GAAP Reconciliation 3Q23 and Sept YTD 23........3 Table 2b: GAAP to Non-GAAP Reconciliation 3Q22 and Sept YTD 22........4 Table 3: Sales - Current Year and Prior Year by Quarter...........................5 Table 3a: Sales – U.S. / Ex- U.S. 3Q23........................................................6 Table 3b: Sales – U.S. / Ex- U.S. Sept YTD 23.............................................7 Table 3c: Sales – Pharmaceutical Geographic Split.....................................8 Table 4: Other (Income) Expense ..............................................................9 -- 1 of 10 -- Sales 15,962 $ 14,959 $ 7% 45,485 $ 45,453 $ – Costs, Expenses and Other Cost of sales 4,264 3,934 8% 12,214 13,530 -10% Selling, general and administrative 2,519 2,520 – 7,700 7,355 5% Research and development 3,307 4,399 -25% 20,904 9,773 * Restructuring costs 126 94 34% 344 288 19% Other (income) expense, net 126 429 -71% 388 1,576 -75% Income Before Taxes 5,620 3,583 57% 3,935 12,931 -70% Taxes on Income 870 330 2,332 1,423 Net Income 4,750 3,253 46% 1,603 11,508 -86% Less: Net Income Attributable to Noncontrolling Interests 5 5 12 6 Net Income Attributable to Merck & Co., Inc. 4,745 $ 3,248 $ 46% 1,591 $ 11,502 $ -86% Earnings per Common Share Assuming Dilution 1.86 $ 1.28 $ 45% 0.62 $ 4.53 $ -86% Average Shares Outstanding Assuming Dilution 2,546 2,542 2,549 2,540 Tax Rate 15.5% 9.2% 59.3% 11.0% * 100% or greater MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 GAAP % Change GAAP % Change 3Q23 3Q22 Sep YTD 2023 Sep YTD 2022 1 -- 2 of 10 -- Sales 14,487 $ 15,035 $ 15,962 $ 45,485 $ 15,901 $ 14,593 $ 14,959 $ 45,453 $ 13,830 $ 59,283 $ 7% – Costs, Expenses and Other Cost of sales 3,926 4,024 4,264 12,214 5,380 4,216 3,934 13,530 3,881 17,411 8% -10% Selling, general and administrative 2,479 2,702 2,519 7,700 2,323 2,512 2,520 7,355 2,687 10,042 – 5% Research and development 4,276 13,321 3,307 20,904 2,576 2,798 4,399 9,773 3,775 13,548 -25% * Restructuring costs 67 151 126 344 53 142 94 288 49 337 34% 19% Other (income) expense, net 89 172 126 388 708 438 429 1,576 (75) 1,501 -71% -75% Income (Loss) Before Taxes 3,650 (5,335) 5,620 3,935 4,861 4,487 3,583 12,931 3,513 16,444 57% -70% Income Tax Provision 825 637 870 2,332 554 538 330 1,423 495 1,918 Net Income (Loss) 2,825 (5,972) 4,750 1,603 4,307 3,949 3,253 11,508 3,018 14,526 46% -86% Less: Net Income (Loss) Attributable to Noncontrolling Interests 4 3 5 12 (3) 5 5 6 1 7 Net Income (Loss) Attributable to Merck & Co., Inc. 2,821 $ (5,975) $ 4,745 $ 1,591 $ 4,310 $ 3,944 $ 3,248 $ 11,502 $ 3,017 $ 14,519 $ 46% -86% Earnings (Loss) per Common Share Assuming Dilution (1) 1.11 $ (2.35) $ 1.86 $ 0.62 $ 1.70 $ 1.55 $ 1.28 $ 4.53 $ 1.18 $ 5.71 $ 45% -86% Average Shares Outstanding Assuming Dilution (1) 2,551 2,539 2,546 2,549 2,537 2,540 2,542 2,540 2,548 2,542 Tax Rate 22.6% -11.9% 15.5% 59.3% 11.4% 12.0% 9.2% 11.0% 14.1% 11.7% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. 2022 Sep YTD Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) % Change 3Q Sep YTD (1) Because the company recorded a net loss in the second quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. 2023 2Q 3Q Sep YTD 1Q 1Q 2Q 3Q 4Q Full Year 2 -- 3 of 10 -- Third Quarter Cost of sales 4,264 $ 552 33 585 3,679 $ Selling, general and administrative 2,519 17 40 57 2,462 Research and development 3,307 10 10 3,297 Restructuring costs 126 126 126 – Other (income) expense, net 126 (24) 17 (7) 133 Income Before Taxes 5,620 (555) (199) (17) (771) 6,391 Income Tax Provision (Benefit) 870 (53) (4) (32) (4) (4) (4) (89) 959 Net Income 4,750 (502) (167) (13) (682) 5,432 Net Income Attributable to Merck & Co., Inc. 4,745 (502) (167) (13) (682) 5,427 Earnings per Common Share Assuming Dilution 1.86 $ (0.20) (0.07) – (0.27) 2.13 $ Tax Rate 15.5% 15.0% Sep YTD Cost of sales 12,214 $ 1,564 94 1,658 10,556 $ Selling, general and administrative 7,700 62 93 155 7,545 Research and development 20,904 29 1 30 20,874 Restructuring costs 344 344 344 – Other (income) expense, net 388 (12) (218) 573 (3) 343 45 Income Before Taxes 3,935 (1,643) (532) 218 (573) (2,530) 6,465 Income Tax Provision (Benefit) 2,332 (249) (4) (88) (4) 47 (4) (60) (4) (350) 2,682 Net Income 1,603 (1,394) (444) 171 (513) (2,180) 3,783 Net Income Attributable to Merck & Co., Inc. 1,591 (1,394) (444) 171 (513) (2,180) 3,771 Earnings per Common Share Assuming Dilution 0.62 $ (0.55) (0.18) 0.07 (0.20) (0.86) 1.48 $ Tax Rate 59.3% 41.5% Only the line items that are affected by non-GAAP adjustments are shown. Adjustment Subtotal Non-GAAP MERCK & CO., INC. THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Table 2a Certain Other Items Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income, partially offset by an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. Additionally, the nine-month period includes a $37 million loss on the sale of a business. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation. (4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. 3 -- 4 of 10 -- Third Quarter Cost of sales 3,934 $ 446 54 500 3,434 $ Selling, general and administrative 2,520 22 26 48 2,472 Research and development 4,399 902 1 903 3,496 Restructuring costs 94 94 94 – Other (income) expense, net 429 (26) 350 324 105 Income Before Taxes 3,583 (1,344) (175) (350) (1,869) 5,452 Income Tax Provision (Benefit) 330 (302) (3) (35) (3) (77) (3) (414) 744 Net Income 3,253 (1,042) (140) (273) (1,455) 4,708 Net Income Attributable to Merck & Co., Inc. 3,248 (1,042) (140) (273) (1,455) 4,703 Earnings per Common Share Assuming Dilution 1.28 $ (0.40) (0.06) (0.11) (0.57) 1.85 $ Tax Rate 9.2% 13.6% Sep YTD Cost of sales 13,530 $ 1,577 167 1,744 11,786 $ Selling, general and administrative 7,355 137 74 211 7,144 Research and development 9,773 936 30 966 8,807 Restructuring costs 288 288 288 – Other (income) expense, net 1,576 (138) 1,268 1,130 446 Income Before Taxes 12,931 (2,512) (559) (1,268) (4,339) 17,270 Income Tax Provision (Benefit) 1,423 (587) (3) (97) (3) (281) (3) (965) 2,388 Net Income 11,508 (1,925) (462) (987) (3,374) 14,882 Net Income Attributable to Merck & Co., Inc. 11,502 (1,925) (462) (987) (3,374) 14,876 Earnings per Common Share Assuming Dilution 4.53 $ (0.76) (0.18) (0.39) (1.33) 5.86 $ Tax Rate 11.0% 13.8% Only the line items that are affected by non-GAAP adjustments are shown. Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses for the three and nine month periods primarily reflect $887 million of intangible asset impairment charges largely related to nemtabrutinib, which was obtained as part of the 2020 ArQule, Inc. acquisition, and expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the three and nine month periods primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi- Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Adjustment Subtotal MERCK & CO., INC. THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2022 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b 4 -- 5 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2023 2022 3Q Sep YTD 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $14,487 $15,035 $15,962 $45,485 $15,901 $14,593 $14,959 $45,453 $13,830 $59,283 7 9 - 3 PHARMACEUTICAL 12,721 13,457 14,263 40,442 14,107 12,756 12,963 39,826 12,180 52,005 10 11 2 4 Oncology Keytruda 5,795 6,271 6,338 18,403 4,809 5,252 5,426 15,487 5,450 20,937 17 17 19 21 Alliance Revenue – Lynparza (2) 275 310 299 884 266 275 284 825 292 1,116 5 6 7 10 Alliance Revenue – Lenvima (2) 232 242 260 734 227 231 202 660 216 876 29 30 11 13 Welireg 42 50 54 146 18 27 38 83 40 123 43 43 77 77 Alliance Revenue – Reblozyl (3) 43 47 52 142 52 33 39 124 41 166 35 35 14 14 Vaccines (4) Gardasil / Gardasil 9 1,972 2,458 2,585 7,015 1,460 1,674 2,294 5,428 1,470 6,897 13 16 29 34 ProQuad / M-M-R II / Varivax 528 582 713 1,823 470 578 668 1,716 526 2,241 7 6 6 6 RotaTeq 297 131 156 584 216 173 256 644 139 783 -39 -39 -9 -8 Vaxneuvance 106 168 214 488 5 12 16 32 138 170 * * * * Pneumovax 23 96 92 140 327 173 153 131 457 145 602 6 4 -28 -27 Vaqta 40 42 69 151 36 35 64 134 39 173 8 9 12 13 Hospital Acute Care Bridion 487 502 424 1,413 395 426 423 1,244 441 1,685 - - 14 15 Prevymis 129 143 157 430 94 103 114 310 118 428 38 38 39 41 Dificid 65 76 74 215 52 66 77 196 67 263 -4 -4 10 10 Primaxin 80 53 41 174 58 64 63 185 54 239 -35 -31 -6 - Noxafil 60 55 51 167 57 60 62 180 58 238 -18 -12 -7 -1 Zerbaxa 50 54 53 157 30 46 43 120 49 169 23 22 31 33 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 99 68 92 259 72 98 88 258 82 341 5 5 - - Adempas (6) 59 65 65 189 61 63 57 181 57 238 15 11 5 7 Virology Lagevrio 392 203 640 1,236 3,247 1,177 436 4,859 825 5,684 47 51 -75 -73 Isentress / Isentress HD 123 136 119 377 158 147 161 466 167 633 -27 -27 -19 -17 Neuroscience Belsomra 56 63 58 176 69 69 62 199 59 258 -6 -4 -11 -6 Immunology Simponi 180 180 179 539 186 181 173 540 166 706 3 -2 - - Remicade 51 48 45 144 61 53 49 163 44 207 -8 -10 -12 -10 Diabetes (7) Januvia 551 511 581 1,642 779 756 717 2,252 561 2,813 -19 -17 -27 -24 Janumet 329 354 255 937 454 476 417 1,347 353 1,700 -39 -38 -30 -28 Other Pharmaceutical (8) 584 553 549 1,690 602 528 603 1,736 583 2,319 -9 -7 -3 - ANIMAL HEALTH 1,491 1,456 1,400 4,347 1,482 1,467 1,371 4,320 1,230 5,550 2 2 1 3 Livestock 849 807 874 2,530 832 826 829 2,486 814 3,300 5 7 2 6 Companion Animal 642 649 526 1,817 650 641 542 1,834 416 2,250 -3 -4 -1 - Other Revenues (9) 275 122 299 696 312 370 625 1,307 420 1,728 -52 -18 -47 -19 *200% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (7) Total Diabetes sales were $950 million, $951 million and $924 million in the first, second and third quarter of 2023, respectively, and $1,305 million, $1,300 million and $1,231 million in the first, second and third quarter of 2022, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $51 million, $3 million and $65 million in the first, second and third quarter of 2023, respectively, and $114 million, $32 million and $10 million in the first, second and third quarter of 2022, respectively. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022. (4) Total Vaccines sales were $3,133 million, $3,557 million and $4,002 million in the first, second and third quarter of 2023, respectively, and $2,481 million, $2,709 million and $3,552 million in the first, second and third quarter of 2022, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. 5 -- 6 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES THIRD QUARTER 2023 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 3Q 2023 3Q 2022 % Change 3Q 2023 3Q 2022 % Change 3Q 2023 3Q 2022 % Change TOTAL SALES (1) $15,962 $14,959 7 $7,715 $7,322 5 $8,247 $7,637 8 PHARMACEUTICAL 14,263 12,963 10 7,153 6,620 8 7,110 6,343 12 Oncology Keytruda 6,338 5,426 17 3,795 3,331 14 2,543 2,095 21 Alliance Revenue – Lynparza (2) 299 284 5 153 144 7 146 140 4 Alliance Revenue – Lenvima (2) 260 202 29 160 142 13 100 60 67 Welireg 54 38 43 51 38 35 3 - Alliance Revenue – Reblozyl 52 39 35 43 32 34 10 7 42 Vaccines (3) Gardasil / Gardasil 9 2,585 2,294 13 838 957 -12 1,746 1,337 31 ProQuad / M-M-R II / Varivax 713 668 7 567 532 7 146 136 7 Vaxneuvance 214 16 * 182 15 * 33 1 * RotaTeq 156 256 -39 108 154 -30 48 102 -53 Pneumovax 23 140 131 6 42 68 -39 98 63 55 Vaqta 69 64 8 32 27 18 37 36 1 Hospital Acute Care Bridion 424 423 - 265 233 14 159 190 -17 Prevymis 157 114 38 70 49 43 87 64 35 Dificid 74 77 -4 69 72 -3 5 6 -20 Zerbaxa 53 43 23 29 24 19 24 19 27 Noxafil 51 62 -18 4 13 -71 47 49 -3 Primaxin 41 63 -35 N/M 41 63 -35 Cardiovascular Alliance Revenue - Adempas/Verquvo (4) 92 88 5 96 85 13 -4 3 * Adempas (5) 65 57 15 65 57 15 Virology Lagevrio 640 436 47 640 436 47 Isentress / Isentress HD 119 161 -27 58 68 -15 61 93 -35 Neuroscience Belsomra 58 62 -6 23 20 12 35 42 -15 Immunology Simponi 179 173 3 179 173 3 Remicade 45 49 -8 45 49 -8 Diabetes (6) Januvia 581 717 -19 328 332 -1 252 385 -34 Janumet 255 417 -39 43 90 -52 211 327 -35 Other Pharmaceutical (7) 549 603 -9 197 194 2 353 410 -14 ANIMAL HEALTH 1,400 1,371 2 462 475 -3 938 896 5 Livestock 874 829 5 205 186 10 669 643 4 Companion Animal 526 542 -3 257 289 -11 269 253 6 Other Revenues (8) 299 625 -52 100 227 -56 199 398 -50 *200% or greater N/M - Not Meaningful (6) Total Diabetes sales were $924 million in the third quarter of 2023 and $1,231 million in the third quarter of 2022. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $65 million in the third quarter of 2023 and $10 million in the third quarter of 2022. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Total Vaccines sales were $4,002 million in the third quarter of 2023 and $3,552 million in the third quarter of 2022. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. 6 -- 7 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES SEPTEMBER YEAR-TO-DATE 2023 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b Global U.S. International Sep YTD 2023 Sep YTD 2022 % Change Sep YTD 2023 Sep YTD 2022 % Change Sep YTD 2023 Sep YTD 2022 % Change TOTAL SALES (1) $45,485 $45,453 - $21,393 $20,927 2 $24,092 $24,526 -2 PHARMACEUTICAL 40,442 39,826 2 19,840 19,119 4 20,602 20,707 -1 Oncology Keytruda 18,403 15,487 19 11,142 9,307 20 7,261 6,180 17 Alliance Revenue – Lynparza (2) 884 825 7 439 427 3 445 397 12 Alliance Revenue – Lenvima (2) 734 660 11 476 426 12 258 235 10 Welireg 146 83 77 141 83 70 6 - Alliance Revenue – Reblozyl (3) 142 124 14 108 87 24 33 37 -10 Vaccines (4) Gardasil / Gardasil 9 7,015 5,428 29 1,718 1,803 -5 5,297 3,624 46 ProQuad / M-M-R II / Varivax 1,823 1,716 6 1,435 1,337 7 388 379 2 RotaTeq 584 644 -9 381 427 -11 203 218 -7 Vaxneuvance 488 32 * 423 31 * 65 1 * Pneumovax 23 327 457 -28 105 280 -63 223 177 26 Vaqta 151 134 12 91 72 25 60 62 -3 Hospital Acute Care Bridion 1,413 1,244 14 841 665 27 572 579 -1 Prevymis 430 310 39 186 136 37 244 174 40 Dificid 215 196 10 199 184 8 16 12 33 Primaxin 174 185 -6 2 1 69 173 185 -6 Noxafil 167 180 -7 29 39 -26 138 141 -2 Zerbaxa 157 120 31 86 64 33 71 55 29 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 259 258 - 249 244 2 10 14 -28 Adempas (6) 189 181 5 189 181 5 Virology Lagevrio 1,236 4,859 -75 1,523 -100 1,236 3,336 -63 Isentress / Isentress HD 377 466 -19 165 196 -16 212 270 -21 Neuroscience Belsomra 176 199 -11 60 60 - 117 139 -16 Immunology Simponi 539 540 - 539 540 - Remicade 144 163 -12 144 163 -12 Diabetes (7) Januvia 1,642 2,252 -27 842 958 -12 800 1,294 -38 Janumet 937 1,347 -30 182 258 -30 755 1,089 -31 Other Pharmaceutical (8) 1,690 1,736 -3 540 511 6 1,147 1,225 -6 ANIMAL HEALTH 4,347 4,320 1 1,418 1,425 -1 2,929 2,894 1 Livestock 2,530 2,486 2 543 521 4 1,987 1,965 1 Companion Animal 1,817 1,834 -1 875 904 -3 942 929 1 Other Revenues (9) 696 1,307 -47 135 383 -65 561 925 -39 *200% or greater (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $2,826 million and $3,836 million on a global share basis for September YTD 2023 and 2022, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $118 million and $156 million on a global share basis for September YTD 2023 and 2022, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022. (4) Total Vaccines sales were $10,692 million and $8,743 million on a global share basis for September YTD 2023 and 2022, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 7 -- 8 of 10 -- MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c 2023 2022 % Change 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year 3Q Sep YTD TOTAL PHARMACEUTICAL $12,721 $13,457 $14,263 $40,442 $14,107 $12,756 $12,963 $39,826 $12,180 $52,005 10 2 United States 6,117 6,570 7,153 19,840 6,773 5,726 6,620 19,119 5,871 24,989 8 4 % Pharmaceutical Sales 48.1% 48.8% 50.1% 49.1% 48.0% 44.9% 51.1% 48.0% 48.2% 48.1% Europe (1) 2,326 2,401 2,497 7,224 3,309 2,677 2,427 8,412 2,494 10,906 3 -14 % Pharmaceutical Sales 18.3% 17.8% 17.5% 17.9% 23.5% 21.0% 18.7% 21.1% 20.5% 21.0% China 1,694 1,887 1,674 5,255 1,113 1,355 1,419 3,887 1,216 5,102 18 35 % Pharmaceutical Sales 13.3% 14.0% 11.7% 13.0% 7.9% 10.6% 10.9% 9.8% 10.0% 9.8% Japan 737 652 1,062 2,451 965 1,092 653 2,710 832 3,542 63 -10 % Pharmaceutical Sales 5.8% 4.8% 7.4% 6.1% 6.8% 8.6% 5.0% 6.8% 6.8% 6.8% Asia Pacific (other than China and Japan) 703 705 636 2,045 786 854 702 2,342 691 3,034 -9 -13 % Pharmaceutical Sales 5.5% 5.2% 4.5% 5.1% 5.6% 6.7% 5.4% 5.9% 5.7% 5.8% Latin America 470 566 696 1,731 435 453 511 1,399 472 1,871 36 24 % Pharmaceutical Sales 3.7% 4.2% 4.9% 4.3% 3.1% 3.6% 3.9% 3.5% 3.9% 3.6% Eastern Europe/Middle East/Africa 381 370 301 1,052 450 339 360 1,149 320 1,469 -16 -8 % Pharmaceutical Sales 3.0% 2.7% 2.1% 2.6% 3.2% 2.7% 2.8% 2.9% 2.6% 2.8% Canada 141 127 133 401 189 166 166 521 158 678 -20 -23 % Pharmaceutical Sales 1.1% 0.9% 0.9% 1.0% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% Other 152 179 111 443 87 94 105 287 126 414 6 54 % Pharmaceutical Sales 1.2% 1.6% 0.9% 0.9% 0.6% 0.6% 0.9% 0.7% 1.0% 0.8% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 3Q23 3Q22 Sep YTD 2023 Sep YTD 2022 Interest income (73) $ (40) $ (295) $ (62) $ Interest expense 317 244 836 727 Exchange losses 85 96 208 220 Loss (income) from investments in equity securities, net (1) 33 371 (240) 1,361 Net periodic defined benefit plan (credit) cost other than service cost (138) (60) (364) (208) Other, net (98) (182) 243 (462) Total 126 $ 429 $ 388 $ 1,576 $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --